Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) Idarubicin hydrochloride injection , USP 5mg/5mL vial (West-ward/ Hikma)
Section 19A approved medicine
(Approval lapsed) Idarubicin hydrochloride injection , USP 5mg/5mL vial (West-ward/ Hikma)
Section 19A approval holder
Orspec Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Expired
Medicines in short supply/unavailable
ZAVEDOS idarubicin hydrochloride 5mg/5mL injection vial ARTG: 67397
Indication(s)
Idarubicin Hydrochloride injection, USP in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults.
Images
